These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 30326563)

  • 1. BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression.
    Kim SH; Ryu H; Ock CY; Suh KJ; Lee JY; Kim JW; Lee JO; Kim JW; Kim YJ; Lee KW; Bang SM; Kim JH; Lee JS; Ahn JB; Kim KJ; Rha SY
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30326563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to FGFR1-targeted therapy leads to autophagy via TAK1/AMPK activation in gastric cancer.
    Peng R; Chen Y; Wei L; Li G; Feng D; Liu S; Jiang R; Zheng S; Chen Y
    Gastric Cancer; 2020 Nov; 23(6):988-1002. PubMed ID: 32617693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo.
    Boichuk S; Galembikova A; Dunaev P; Micheeva E; Valeeva E; Novikova M; Khromova N; Kopnin P
    Molecules; 2018 Oct; 23(10):. PubMed ID: 30326595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma.
    Scheller T; Hellerbrand C; Moser C; Schmidt K; Kroemer A; Brunner SM; Schlitt HJ; Geissler EK; Lang SA
    Br J Cancer; 2015 Mar; 112(5):841-50. PubMed ID: 25688743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Phosphatidylinositol 3-kinase (PI3K) Signaling Synergistically Potentiates Antitumor Efficacy of Paclitaxel and Overcomes Paclitaxel-Mediated Resistance in Cervical Cancer.
    Liu JJ; Ho JY; Lee HW; Baik MW; Kim O; Choi YJ; Hur SY
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31295843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockdown of Bcl-2-Associated Athanogene-3 Can Enhance the Efficacy of BGJ398 via Suppressing Migration and Inducing Apoptosis in Gastric Cancer.
    Li K; Deng X; Feng G; Chen Y
    Dig Dis Sci; 2021 Sep; 66(9):3036-3044. PubMed ID: 33089486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.
    Lamont FR; Tomlinson DC; Cooper PA; Shnyder SD; Chester JD; Knowles MA
    Br J Cancer; 2011 Jan; 104(1):75-82. PubMed ID: 21119661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer.
    Weickhardt AJ; Lau DK; Hodgson-Garms M; Lavis A; Jenkins LJ; Vukelic N; Ioannidis P; Luk IY; Mariadason JM
    BMC Cancer; 2022 May; 22(1):478. PubMed ID: 35501832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of fibroblast growth factor receptor 1 correlates inversely with the efficacy of single-agent fibroblast growth factor receptor-specific inhibitors in pancreatic cancer.
    Lin Q; Serratore A; Perri J; Roy Chaudhuri T; Qu J; Ma WW; Kandel ES; Straubinger RM
    Br J Pharmacol; 2024 May; 181(9):1383-1403. PubMed ID: 37994108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complexity of FGFR signalling in metastatic urothelial cancer.
    Rodriguez-Vida A; Saggese M; Hughes S; Rudman S; Chowdhury S; Smith NR; Lawrence P; Rooney C; Dougherty B; Landers D; Kilgour E; Arkenau HT
    J Hematol Oncol; 2015 Oct; 8():119. PubMed ID: 26497743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on
    Sternberg CN; Petrylak DP; Bellmunt J; Nishiyama H; Necchi A; Gurney H; Lee JL; van der Heijden MS; Rosenbaum E; Penel N; Pang ST; Li JR; García Del Muro X; Joly F; Pápai Z; Bao W; Ellinghaus P; Lu C; Sierecki M; Coppieters S; Nakajima K; Ishida TC; Quinn DI
    J Clin Oncol; 2023 Jan; 41(3):629-639. PubMed ID: 36240478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ASP5878, a selective FGFR inhibitor, to treat FGFR3-dependent urothelial cancer with or without chemoresistance.
    Kikuchi A; Suzuki T; Nakazawa T; Iizuka M; Nakayama A; Ozawa T; Kameda M; Shindoh N; Terasaka T; Hirano M; Kuromitsu S
    Cancer Sci; 2017 Feb; 108(2):236-242. PubMed ID: 27885740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations.
    Lima NC; Atkinson E; Bunney TD; Katan M; Huang PH
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32370101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastric cancer mesenchymal stem cells promote tumor glycolysis and chemoresistance by regulating B7H3 in gastric cancer cells.
    Gao Q; Huang C; Liu T; Yang F; Chen Z; Sun L; Zhao Y; Wang M; Luo L; Zhou C; Zhu W
    J Cell Biochem; 2024 Mar; 125(3):e30521. PubMed ID: 38226525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.
    Rodón J; Damian S; Furqan M; García-Donas J; Imai H; Italiano A; Spanggaard I; Ueno M; Yokota T; Veronese ML; Oliveira N; Li X; Gilmartin A; Schaffer M; Goyal L
    Nat Med; 2024 Jun; 30(6):1645-1654. PubMed ID: 38710951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.
    Kim SM; Kim H; Yun MR; Kang HN; Pyo KH; Park HJ; Lee JM; Choi HM; Ellinghaus P; Ocker M; Paik S; Kim HR; Cho BC
    Oncogenesis; 2016 Jul; 5(7):e241. PubMed ID: 27429073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of Glycolysis by MCM10 Increases Stemness and Paclitaxel Resistance in Gastric Cancer Cells.
    Wu Z; Fang Y; Wu J; Wang J; Ling Y; Liu T; Tong Q; Yao Y
    Turk J Gastroenterol; 2023 Nov; 34(11):1107-1115. PubMed ID: 37860833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elemene Injection Overcomes Paclitaxel Resistance in Breast Cancer through AR/RUNX1 Signal: Network Pharmacology and Experimental Validation.
    Gu X; Xu L; Fu Y; Fan S; Huang T; Yu J; Chen J; Sui X; Xie X
    Curr Pharm Des; 2024 Jun; ():. PubMed ID: 38918989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioinformatics approach combined with experimental verification reveals OAS3 gene implicated in paclitaxel resistance in head and neck cancer.
    Caglar HO; Aytatli A; Barlak N; Aydin Karatas E; Tatar A; Sahin A; Karatas OF
    Head Neck; 2024 May; ():. PubMed ID: 38752376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A distinct subset of urothelial cells with enhanced EMT features promotes chemotherapy resistance and cancer recurrence by increasing COL4A1-ITGB1 mediated angiogenesis.
    Guo J; Ma X; Liu D; Wang F; Xia J; Zhang B; Zhao P; Zhong F; Chen L; Long Q; Jiang L; Zhang S; Liao N; Wang J; Wu W; Sun J; Huang M; Cheng Z; Huang G; Zou C
    Drug Resist Updat; 2024 Jul; 76():101116. PubMed ID: 38968684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.